PharmaEssentia's Puerto Rico Bet: A New Hub for US-Taiwan Bio-Alliance

BURLINGTON, MA – April 02, 2026

Taiwan-based biopharmaceutical company PharmaEssentia Corporation has finalized an investment agreement to construct a new, state-of-the-art manufacturing facility in Toa Baja, Puerto Rico. The move, celebrated in a signing ceremony on March 26, marks a significant step in the company's strategy to create a dual-site manufacturing network spanning Taiwan and the United States, a decision designed to fortify its global supply chain and fuel long-term growth.

The ceremony was attended by a host of high-level officials, reflecting the project's strategic importance. Participants included Puerto Rico Governor Jenniffer González Colón and representatives from the U.S. Department of Commerce and the Taipei Economic and Cultural Office (TECO). Their presence underscored the deepening bilateral collaboration between the U.S. and Taiwan in the critical life sciences sector.

PharmaEssentia Chairperson Dr. Ching-Leou Teng set a forward-looking tone at the event. "This is not just a closing — it is the start of a long-term partnership and a clear demonstration of our commitment to patients," she stated, framing the investment as more than a business transaction.

Puerto Rico's Biopharma Renaissance

PharmaEssentia's decision to anchor its U.S. manufacturing presence in Puerto Rico is a major vote of confidence in the island's long-established and thriving biopharmaceutical ecosystem. Often called the "Medicine Cabinet of the USA," Puerto Rico has cultivated its position as a global leader in pharmaceutical production for over 70 years. The industry is a cornerstone of its economy, contributing to roughly 30% of its GDP and a staggering 74% of its total exports in fiscal year 2024.

The island is a manufacturing hub for 11 of the world's top 20 pharmaceutical companies, including giants like Amgen, Bristol Myers Squibb, and Eli Lilly. This concentration has created a robust infrastructure of specialized contractors, FDA-certified cold chain logistics, and a deep reservoir of industry expertise.

This investment was championed by Puerto Rico's leadership. “This investment reaffirms Puerto Rico’s position as a reliable and competitive U.S. jurisdiction for advanced biopharmaceutical manufacturing," said Governor Jenniffer González Colón. "We continue to attract projects that strengthen our economy, create specialized jobs, and contribute to the resilience of the United States’ supply of critical medicines.”

Fueling this growth is a highly competitive incentive structure under Puerto Rico's Act 60, which offers benefits like a 4% fixed corporate tax rate, significant property tax exemptions, and R&D tax credits. While the island faces challenges in retaining its highly skilled, bilingual STEM workforce—which produces over 25,000 graduates annually—the consistent influx of major investments from companies like PharmaEssentia helps create high-value jobs and anchor talent locally.

A Strategic Move for Global Supply Chain Resilience

The new facility is the cornerstone of PharmaEssentia's plan to mitigate global supply chain risks, a priority that has become paramount for the pharmaceutical industry following the disruptions of the COVID-19 pandemic. By establishing a second major manufacturing site in a U.S. jurisdiction, the company diversifies its production base away from its primary facility in Taichung, Taiwan.

This dual-site strategy is a direct response to the industry-wide push for greater resilience through "nearshoring" and geographic diversification. Operating in Puerto Rico provides PharmaEssentia with the stability of U.S. federal law, robust intellectual property protection, and tariff-free access to the vast U.S. market—all while reducing risks associated with geopolitical tensions or natural disasters that could impact a single location.

“Expanding manufacturing capacity outside Taiwan is a core strategic priority for PharmaEssentia,” said Dr. Ko-Chung Lin, the company's Founder and Chief Executive Officer. “We are proud to establish U.S.-based manufacturing, with Puerto Rico serving as a key hub to support the U.S. market and our commitment to patients worldwide.”

PharmaEssentia plans for the Toa Baja facility to begin operations in 2027. The site is being designed to mirror the high-quality standards of its Taiwanese counterpart. To ensure a seamless transfer of its proprietary manufacturing processes, personnel from the Puerto Rico facility will undergo intensive training at the Taichung site, fostering operational readiness and maintaining consistent quality across its network.

Bolstering US-Taiwan Economic and Geopolitical Ties

Beyond its corporate and economic implications, PharmaEssentia's investment carries significant geopolitical weight. It represents a tangible example of the strengthening partnership between the United States and Taiwan in critical technology sectors, moving beyond the well-known semiconductor industry into the vital field of biotechnology.

The project aligns with a broader U.S. strategic goal of "de-risking" essential supply chains by encouraging manufacturing in allied nations and domestic territories, thereby reducing dependence on China and other potentially volatile regions. The enthusiastic participation of U.S. and Taiwanese diplomatic officials at the signing ceremony highlighted this strategic dimension.

Director General Chi Yu Chou of TECO Miami emphasized this point, stating that the investment reflects the strengthening economic bonds between the two partners. “The company's dual production strategy embodies the symbiotic partnership between the two sides," he noted. "This project demonstrates the breadth and resilience of Taiwan's industries, extending beyond AI and semiconductors into biotechnology and healthcare. It also underscores the potential for deeper bilateral economic cooperation and the continued global competitiveness of Taiwanese enterprises in high-value sectors.”

Impact on Patients and Future Growth

Ultimately, the new facility is intended to secure the supply of life-altering medicines for patients. The investment will directly support the production and distribution of products like BESREMi® (ropeginterferon alfa-2b-njft), the company’s FDA-approved treatment for adults with polycythemia vera (PV), a rare, chronic blood cancer. A resilient, U.S.-based supply chain ensures that patients in one of the company's largest markets will have reliable access to treatment, insulated from potential global shipping or production disruptions.

BESREMi® is a key asset for PharmaEssentia, competing in a market that includes established treatments like hydroxyurea and ruxolitinib. By ensuring a stable supply, the company can better support its commercial operations and ongoing clinical development, which includes seeking a label expansion for BESREMi® to treat essential thrombocythemia (ET).

The Puerto Rico facility is not just for one product; it is a long-term investment in the company's future. As a global biopharmaceutical innovator with a diversifying pipeline in hematology, oncology, and immunology, PharmaEssentia is building the infrastructure needed to bring its next generation of biologics from the lab to patients. This strategic expansion positions the company for sustained growth and reinforces its capacity to meet the needs of patients with challenging diseases worldwide.